Table 2.
Summary of clinical trials of EGFR tyrosine kinase inhibitors in development in NSCLC with EGFR mutations
| EGFR tyrosine kinase inhibitor | Phase | Trial registration | Targets | Trial design |
|---|---|---|---|---|
| Lapatinib | II | NCT00528281 | EGFR, HER2 | Single-arm study with pemetrexed |
| Neratinib | II | NCT00266877 | EGFR, HER2 | Three-group study |
| Icotinib (BPI-2009H) | II, III |
NCT01690390 NCT01707329 NCT01516983 NCT01719536 |
EGFR | Monotherapy and with chemotherapy, radiation or other targeted therapies |
| Afatinib | II, III | Multiple studies | Pan-HER family | |
| Dacomitinib (PF00299804) | III |
NCT01774721 NCT01360554 |
Pan-HER family | Monotherapy versus gefitinib or erlotinib |
| Poziotinib (HM781-36B) | II |
NCT01819428 NCT01718847 |
Pan-HER and TEC family | First- and second-line monotherapy |
| AZD9291 | I | NCT01802632 | EGFR mutation specific | Monotherapy in previously treated EGFR mutant NSCLC |
| CO-1686 | I, II | NCT01526928 | EGFR mutation specific | Monotherapy in previously treated EGFR mutant NSCLC |
| HM61713 | I | NCT01588145 | EGFR mutation specific | Monotherapy in previously treated EGFR mutant NSCLC |
| AP26113 | I, II | NCT01449461 | Dual ALK and EGFR inhibitor | Monotherapy in NSCLC with ALK gene rearrangement or mutant EGFR |
Abbreviations: EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor; NSCLC, non-small-cell lung carcinoma.